PLUR Stock Overview
A biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.19 |
| 52 Week High | US$30.71 |
| 52 Week Low | US$15.04 |
| Beta | 1.45 |
| 11 Month Change | -6.50% |
| 3 Month Change | 19.91% |
| 1 Year Change | -24.13% |
| 33 Year Change | -83.40% |
| 5 Year Change | -87.73% |
| Change since IPO | -97.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| PLUR | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | -26.3% | -0.1% | 3.3% |
| 1Y | -24.1% | -18.5% | 2.7% |
Return vs Industry: PLUR underperformed the IL Biotechs industry which returned 14.9% over the past year.
Return vs Market: PLUR underperformed the IL Market which returned 14.6% over the past year.
Price Volatility
| PLUR volatility | |
|---|---|
| PLUR Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 7.1% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: PLUR's share price has been volatile over the past 3 months.
Volatility Over Time: PLUR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 129 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
Pluri Inc. Fundamentals Summary
| PLUR fundamental statistics | |
|---|---|
| Market cap | ₪115.18m |
| Earnings (TTM) | -₪88.98m |
| Revenue (TTM) | ₪1.33m |
83.9x
P/S Ratio-1.3x
P/E RatioIs PLUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUR income statement (TTM) | |
|---|---|
| Revenue | US$357.00k |
| Cost of Revenue | US$9.00k |
| Gross Profit | US$348.00k |
| Other Expenses | US$24.30m |
| Earnings | -US$23.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.60 |
| Gross Margin | 97.48% |
| Net Profit Margin | -6,708.40% |
| Debt/Equity Ratio | 368.8% |
How did PLUR perform over the long term?
See historical performance and comparison